001     177294
005     20240229133736.0
024 7 _ |a 10.1038/s41375-021-01431-x
|2 doi
024 7 _ |a pmid:34732857
|2 pmid
024 7 _ |a 0887-6924
|2 ISSN
024 7 _ |a 1476-5551
|2 ISSN
024 7 _ |a altmetric:116238167
|2 altmetric
037 _ _ |a DKFZ-2021-02422
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Leypoldt, Lisa B
|0 0000-0002-9248-588X
|b 0
245 _ _ |a Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
260 _ _ |a London
|c 2022
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1646136379_20516
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 36, pages 885–888 (2022)
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Besemer, Britta
|b 1
700 1 _ |a Asemissen, Anne Marie
|b 2
700 1 _ |a Hänel, Mathias
|b 3
700 1 _ |a Blau, Igor Wolfgang
|b 4
700 1 _ |a Görner, Martin
|b 5
700 1 _ |a Ko, Yon-Dschun
|b 6
700 1 _ |a Reinhardt, Hans Christian
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Staib, Peter
|b 8
700 1 _ |a Mann, Christoph
|b 9
700 1 _ |a Lutz, Raphael
|b 10
700 1 _ |a Munder, Markus
|b 11
700 1 _ |a Graeven, Ullrich
|0 0000-0001-6082-7710
|b 12
700 1 _ |a Peceny, Rudolf
|b 13
700 1 _ |a Salwender, Hans
|0 0000-0001-7803-0814
|b 14
700 1 _ |a Jauch, Anna
|b 15
700 1 _ |a Zago, Manola
|b 16
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 17
|u dkfz
700 1 _ |a Tichy, Diana
|0 P:(DE-He78)2ef631585610340ff425c9c31fcabd03
|b 18
|u dkfz
700 1 _ |a Bokemeyer, Carsten
|b 19
700 1 _ |a Goldschmidt, Hartmut
|b 20
700 1 _ |a Weisel, Katja C
|0 0000-0001-9422-6614
|b 21
773 _ _ |a 10.1038/s41375-021-01431-x
|0 PERI:(DE-600)2008023-2
|p 885–888
|t Leukemia
|v 36
|y 2022
|x 1476-5551
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177294
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)2ef631585610340ff425c9c31fcabd03
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-18
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK ED ES zentral
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21